We all know we are living off the R&D Tax incentive and the monthly cash burn means we may only have a month of cash to last, unless spending softens - which is hard to see happening as the product is being developed, improved and marketed, and the clinical trial being ran and analysed and prepared into meaningful data. Perhaps the marketing spend has been cut-back as focus shifts to negotiating with the big multi-national.
Thoughts on structure of potential different CR options?
It just doesn't feel like they'll raise $3m at say .025c. Is it likely to come on the back of clinical trial results? Is there no raise because of an agreement with a multi-national? Is it a share consolidation? Will you participate in a raise?
Bit of a rushed, non-thought out post sorry, as at work, but keen to hear peoples thoughts on how this next month will play out. I believe an announcement is fairly imminent - if not within the week, then the fortnight.
ALT Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held
